Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI ...

On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...

The appetites of biotech investors for companies expanding in artificial intelligence show no signs of slowing any time soon, as reflected by the stock surge enjoyed by Recursion Pharmaceuticals (RXRX ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. Sep 09, 2020, 07:00am EDT This article is more than 5 years old. Chris Gibson, ...

Recursion Pharmaceuticals uses high-dimensional data and modern approaches to generate predictive results for drug discovery and development. The company has strengthened its tech stack through ...

Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered ...

SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...